Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KETOROLAC HIGH GASTRIC ULCER INCIDENCE SHOULD BE WEIGHED IN SHORT-TERM THERAPY

Executive Summary

KETOROLAC HIGH GASTRIC ULCER INCIDENCE SHOULD BE WEIGHED IN SHORT-TERM THERAPY, according to the authors of a study to be published in the January issue of Epidemiology. The study, "Gastroduodenal toxicity of different nonsteroidal anti- inflammatory drugs," by researchers Giuseppe Traversa, Instituto Superiore di Sanua, Rome, Alexander Walker, Harvard School of Public Health, et al., concluded that the "use of ketorolac appears to carry a greater gastrotoxicity than other NSAIDs." Syntex markets ketorolac in oral and intramuscular forms as Toradol.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS025482

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel